Jazz Pharma Ruling Clears US Roadblock for Rival Narcolepsy Drug
A US appeals court ordered Jazz Pharmaceuticals on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the FDA's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals.
Reuters Health Information
source https://www.medscape.com/viewarticle/988755?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/988755?src=rss
Comments
Post a Comment